Denmark-based Novo Nordisk Plans $65 Million Expansion at Clayton, North Carolina, Campus

SourceArea Development
Date Published02/06/2018
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Diabetes Finished Products
Parent companyNovo Nordisk
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):24
Year reshoring announced:2018
Capital investment ($):65
Country(ies) from which reshored:Denmark
City reshored to:Clayton
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoreddiabetes products
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Impact on domestic economy, Skilled workforce availability/training
Find Reshoring Articles